InsidersTradesSigma
Track the RVL Pharmaceuticals plc stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, RVL Pharmaceuticals plc has published 29 insider filings. The latest transaction was reported on 23 October 2023 (Cession). Among the most active insiders: Schaub James. All data is openly available.
29
Insider Decl.
n/a
Thresholds
€38m
5 ops.
Buy Volume
€1m
4 ops.
Sell Volume
66Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 23 October 2023
Declarations29 total
9,363,760 shares@ US$0.046166.0% of flowOrdinary SharesSEC:0001754526-23-000002:0
9,363,760 shares@ US$0.046166.0% of flowOrdinary SharesSEC:0001752864-23-000002:0
3,421,537 shares@ US$0.064634.0% of flowOrdinary SharesSEC:0001752864-23-000001:0
3,421,537 shares@ US$0.064634.0% of flowOrdinary SharesSEC:0001754526-23-000001:0
23,730,864 sharesOrdinary SharesSEC:0001104659-23-093104:0
12,000 shares@ US$0.49100.0% of flowOrdinary SharesSEC:0001104659-23-091548:0
40,000 shares0Ordinary SharesSEC:0001104659-23-080117:0
40,000 shares0Ordinary SharesSEC:0001104659-23-080118:0
40,000 shares0Ordinary SharesSEC:0001104659-23-080116:0
5,447 shares@ US$0.8710.3% of flowOrdinary SharesSEC:0001104659-23-063321:0
5,577 shares@ US$0.871.7% of flowOrdinary SharesSEC:0001104659-23-063324:0
1,032,995 shares0Ordinary SharesSEC:0001104659-23-008075:0
1,032,995 shares0Ordinary SharesSEC:0001104659-23-008079:0
1,032,995 shares0Ordinary SharesSEC:0001104659-23-008077:0
9,608 shares@ US$1.2626.0% of flowOrdinary SharesSEC:0001104659-23-007069:0
9,608 shares@ US$1.264.1% of flowOrdinary SharesSEC:0001104659-23-007068:0
75,000 shares0Ordinary SharesSEC:0001104659-22-090049:0
850,000 shares@ US$1.55100.0% of flowOrdinary SharesSEC:0001104659-22-088034:0
Canonical exit: 6 Nov 2022 (T+90)
150,000 shares@ US$1.5584.1% of flowOrdinary SharesSEC:0001104659-22-088038:0
Canonical exit: 6 Nov 2022 (T+90)
8,000,000 shares@ US$1.55100.0% of flowOrdinary SharesSEC:0001104659-22-088025:0
Canonical exit: 6 Nov 2022 (T+90)
8,000,000 shares@ US$1.55100.0% of flowOrdinary SharesSEC:0001104659-22-088030:0
Canonical exit: 6 Nov 2022 (T+90)
8,000,000 shares@ US$1.55100.0% of flowOrdinary SharesSEC:0001104659-22-088033:0
Canonical exit: 6 Nov 2022 (T+90)
5,447 shares@ US$1.4027.6% of flowOrdinary SharesSEC:0001104659-22-063394:0
6,127 shares@ US$1.4030.0% of flowOrdinary SharesSEC:0001104659-22-063392:0
6,273 shares@ US$1.4030.5% of flowOrdinary SharesSEC:0001104659-22-063391:0
25 of 29 declarations
关于 RVL Pharmaceuticals plc
RVL Pharmaceuticals plc 是一家专业制药公司，曾在美国纳斯达克市场上市，并在美国运营，主要业务活动集中在新泽西州布里奇沃特。该公司的商业身份围绕着眼科医学和医疗美学领域未被满足的治疗需求而建立，其最知名的资产是UPNEEQ®（盐酸羟甲唑啉滴眼液）0.1%，这是一种用于治疗成人后天性睑下垂（或称眼睑下垂）的处方药。RVL的模式将产品商业化与技术支持的获取和整合交付相结合，旨在支持临床医生和患者。([rvlpharma.com](https://www.rvlpharma.com/about-us?utm_source=openai)) 从历史角度看，RVL Pharmaceuticals plc 是一家爱尔兰上市公司，但其运营足迹主要在美国。SEC文件将新泽西州布里奇沃特确定为该公司的主要行政办公室，早期的文件也提及了位于赛尔维尔的新泽西州药房业务，该业务支持Upneeq的供应和分销链。这种结构对投资者很重要，因为它突显了一家在爱尔兰注册成立但商业上扎根于美国市场的公司。([ir.rvlpharma.com](https://ir.rvlpharma.com/company-profile?utm_source=openai)) RVL的核心业务是一家专注的专业制药公司，而非广泛多元化的制药平台。其战略依赖于围绕旗舰品牌构建的狭窄产品组合，其中Upneeq是主要的价值驱动因素。该公司针对治疗眼睑下垂及相关美容或功能问题的医生和美容诊所，旨在通过创造性产品、专业商业执行和患者获取工具来差异化自身。在竞争方面，RVL在一个利基市场中运营，其中临床差异化、监管定位和销售团队执行力比规模更重要。([rvlpharma.com](https://www.rvlpharma.com/about-us?utm_source=openai)) 最近最重大的发展是财务困境和重组。2023年，RVL的美国运营子公司进入破产保护程序（Chapter 11），SEC披露文件指出，前上市公司母公司RVL Pharmaceuticals plc 预计将被清算，普通股将被注销，普通股东将无法获得任何补偿。对于市场参与者而言，这是一个关键点：即使公司名称仍出现在历史市场数据或公司参考资料中，其股权故事已因重组过程而发生根本性转变。([sec.gov](https://www.sec.gov/Archives/edgar/data/1739426/000110465923121234/tm2331439d1_8k.htm?utm_source=openai)) 总而言之，RVL Pharmaceuticals plc 应被视为一家在美国运营、在纳斯达克上市的专业制药公司，围绕Upneeq构建，产品组合集中，总部位于新泽西州布里奇沃特，其近期公司历史主要由重组而非增长主导。对于讲法语的投资者而言，关键在于该公司的商业叙述直截了当，但其资本结构和公众股东结果受到2023年重组和清算过程的重大影响。([ir.rvlpharma.com](https://ir.rvlpharma.com/news-releases/rvl-pharmaceuticals-plc-announces-prepackaged-reoganization-of-certain-us-subsidiaries?utm_source=openai))
